The diagnostic and prognostic value of tau-PET in amnestic MCI with different FDG-PET subtypes.

Cecilia Boccalini Silvia Paola CaminitiArturo ChitiGiovanni B FrisoniValentina GaribottoDaniela Peraninull null

Published in: Annals of clinical and translational neurology (2024)

aMCI subjects can differ in metabolic patterns, tau and amyloid pathology, and clinical progression. Here, we complemented with PET tau biomarker the specific brain hypometabolic patterns at the individual level in the prodromal phase, contributing to the patient's classification. Tau PET is the most accurate biomarker in supporting or excluding the AD diagnosis in aMCI across metabolic subtypes and also predicting the risk of decline.

Keyphrases

pet ct
positron emission tomography
pet imaging
computed tomography
cerebrospinal fluid
mild cognitive impairment
machine learning
resting state
case report
high resolution
deep learning
multiple sclerosis
functional connectivity
parkinson disease
brain injury